These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 15694668)
21. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Abd-El Raouf SM; Ibrahim TR Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837 [TBL] [Abstract][Full Text] [Related]
22. STT3A, C1orf24, TFF3: putative markers for characterization of follicular thyroid neoplasms from fine-needle aspirates. Patel MR; Stadler ME; Deal AM; Kim HS; Shores CG; Zanation AM Laryngoscope; 2011 May; 121(5):983-9. PubMed ID: 21520112 [TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation. Atik E; Guray M; Gunesacar R; Ozgur T; Canda T Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099 [TBL] [Abstract][Full Text] [Related]
24. QPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study. Hinsch N; Frank M; Döring C; Vorländer C; Hansmann ML BMC Cancer; 2009 Mar; 9():93. PubMed ID: 19321014 [TBL] [Abstract][Full Text] [Related]
25. Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: distinguishing follicular thyroid carcinoma from adenoma. Sato T; Harao M; Nakano S; Jotsuka T; Suda N; Yamashita J Surgery; 2005 May; 137(5):552-8. PubMed ID: 15855928 [TBL] [Abstract][Full Text] [Related]
26. TFF3-based candidate gene discrimination of benign and malignant thyroid tumors in a region with borderline iodine deficiency. Krause K; Eszlinger M; Gimm O; Karger S; Engelhardt C; Dralle H; Fuhrer D J Clin Endocrinol Metab; 2008 Apr; 93(4):1390-3. PubMed ID: 18198227 [TBL] [Abstract][Full Text] [Related]
27. Molecular classification of thyroid nodules by cytology. Pagedar NA; Chen DH; Wasman JK; Savvides P; Schluchter MD; Wilhelm SM; Lavertu P Laryngoscope; 2008 Apr; 118(4):692-6. PubMed ID: 18094649 [TBL] [Abstract][Full Text] [Related]
28. Galectin-3 is a presurgical marker of human thyroid carcinoma. Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965 [TBL] [Abstract][Full Text] [Related]
29. Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Yasuoka H; Kakudo K; Inohara H; Kuma K; Miyauchi A Pathology; 2005 Aug; 37(4):296-8. PubMed ID: 16194828 [TBL] [Abstract][Full Text] [Related]
30. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570 [TBL] [Abstract][Full Text] [Related]
31. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010 [TBL] [Abstract][Full Text] [Related]
32. Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy. Ippolito A; Vella V; La Rosa GL; Pellegriti G; Vigneri R; Belfiore A Thyroid; 2001 Aug; 11(8):783-7. PubMed ID: 11525273 [TBL] [Abstract][Full Text] [Related]
33. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527 [TBL] [Abstract][Full Text] [Related]
34. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177 [TBL] [Abstract][Full Text] [Related]
35. [Fine-needle aspiration biopsy of the thyroid nodule: uses and limitations]. Hayashi N; Kitaoka M Nihon Rinsho; 2007 Nov; 65(11):2003-7. PubMed ID: 18018562 [TBL] [Abstract][Full Text] [Related]
36. Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas. Nascimento MC; Bisi H; Alves VA; Longatto-Filho A; Kanamura CT; Medeiros-Neto G Endocr Pathol; 2001; 12(3):275-9. PubMed ID: 11740048 [TBL] [Abstract][Full Text] [Related]
37. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Giannini R; Faviana P; Cavinato T; Elisei R; Pacini F; Berti P; Fontanini G; Ugolini C; Camacci T; De Ieso K; Miccoli P; Pinchera A; Basolo F Thyroid; 2003 Aug; 13(8):765-70. PubMed ID: 14558920 [TBL] [Abstract][Full Text] [Related]
38. Overexpression of mir-129-1, miR-146b, mir-183, and mir-197 in follicular thyroid carcinoma and adenoma tissues. Sheikholeslami S; Shabani N; Shivaee S; Tavangar SM; Yeganeh M; Hedayati M; Lotfi J; Gholami H Mol Cell Probes; 2020 Jun; 51():101536. PubMed ID: 32081771 [TBL] [Abstract][Full Text] [Related]
39. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. Saggiorato E; Cappia S; De Giuli P; Mussa A; Pancani G; Caraci P; Angeli A; Orlandi F J Clin Endocrinol Metab; 2001 Nov; 86(11):5152-8. PubMed ID: 11701669 [TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Haghpanah V; Shooshtarizadeh P; Heshmat R; Larijani B; Tavangar SM Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):422-5. PubMed ID: 17122639 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]